Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34469158 | 1.00 | CMA1 (0.45) | CMA1KDM4EHKDC1MEN1KMT2A | |
| SCHEMBL34468997 | 1.00 | CMA1 (0.45) | CMA1KDM4EHKDC1MEN1KMT2A | |
| SCHEMBL22493929 | 0.81 | TSHR (0.54) | KDM4EMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL34469172 | 0.81 | TSHR (0.54) | KDM4EMEN1KMT2ACYP3A4ALDH1A1 | |
| SCHEMBL23731283 | 0.79 | MEN1 (0.42) | CMA1MEN1KMT2AGSK3AGSK3B | |
| SCHEMBL34469269 | 0.79 | MEN1 (0.45) | CMA1MEN1KMT2AHCRTR1HCRTR2 | |
| SCHEMBL22645701 | 0.78 | GSK3A (0.43) | CMA1KDM4EHKDC1MEN1KMT2A | |
| SCHEMBL23326573 | 0.78 | GSK3A (0.43) | CMA1KDM4EHKDC1MEN1KMT2A | |
| SCHEMBL23706943 | 0.76 | CYP3A4 (0.54) | CMA1KDM4EHKDC1MEN1KMT2A | |
| SCHEMBL14239968 | 0.76 | CYP3A4 (0.54) | CMA1KDM4EHKDC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-110177783-B | Hormone receptor modulators for the treatment of metabolic conditions and disorders | 阿德利克斯股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-3681881-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3954684-A1 | PROCESS FOR THE PREPARATION OF HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | Ardelyx, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3504205-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CMA1 4338/4885KDM4E 4023/4885HKDC1 353/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | CMA1 4338/4885KDM4E 4023/4885HKDC1 353/4885 |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | NR1H4, FXR1, FXR2 | CMA1 3635/4885KDM4E 3556/4885HKDC1 600/4885 |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | NR1H4, FXR1, FXR2 | CMA1 3635/4885KDM4E 3556/4885HKDC1 600/4885 |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CMA1 4338/4885KDM4E 4023/4885HKDC1 353/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | CMA1 4338/4885KDM4E 4023/4885HKDC1 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.